May 19, 2010

Final Program Announced for Symposium at Harvard Medical School on the Applications of Ultra-High Pressure in Biotechnology

SOUTH EASTON, Mass., May 19, 2010 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" and the "Company") today announced the final Program for the Symposium it is hosting on Friday, May 21st at Harvard Medical School ("HMS"). Entitled "Applications of Ultra-high Pressure in Biotechnology," the Symposium will be held from 8:30 am -- 5:00 pm in the Rotunda Room of the New Research Building at HMS, 77 Avenue Louis Pasteur, in Boston, MA.

The event is co-hosted by the Laboratory for Innovative Translational Technologies (HC-LITT) and the Central Laboratory (HCCL) of Harvard Catalyst -- The Harvard Clinical and Translational Science Center (Harvard CTSC), and the Proteomics Resource at Harvard School of Public Health. The Symposium is free-of-charge; pre-registration is required.

Mr. Wayne Fritzsche, Chairman of the Board of PBI, said: "Fifteen scientists from academia, government, and industry will present data on applications of cycled ultra-high pressure (pressure cycling technology, or "PCT") in biotechnology. It is expected that attendees will be given an excellent overview of this powerful, proprietary platform and that they will gain a clear understanding of how PCT is currently being used to successfully break through bottlenecks and barriers that are preventing significant advancements in diagnostics and therapeutics."

The announced presentation titles and speakers are:

High Pressure Instruments for Innovation and Discovery

Edmund Y. Ting, B.S.M.E., M.Sc., Sc.D., Pressure BioSciences, Inc., S. Easton, MA 02375

Development of Essential Sample Preparation Techniques in Proteomics Using Ultra-high Pressure

Alexander R. Ivanov, Ph.D.,Harvard School of Public Health, HSPH Proteomics Resource, Department of Genetics and Complex Diseases, Boston, MA 2115

High Pressure Digestion Improves Reproducibility and Differential Expression Monitoring in Proteomic Experiments

E. Bonneil, Institute for Research in Immunology and Cancer, Universite de Montreal, Canada

Application of High Pressure for High Performance Proteomics

Daniel López-Ferrer, Pacific Northwest National Laboratory, Richland, WA

High Pressure Direct Protein Extraction from Tissue -- Trypsin Digest with Pressure Cycling Technology (PCT)

Paul H. Pevsner, Dept. of Pathology, University of Missouri School of Medicine, Columbia, MO

Recovery and Immunoaffinity Enrichment of Integral Membrane Proteins from Metastatic Ovarian Cancer Tissue

Luke Schneider, Target Discovery, Inc., Palo Alto, CA

Application of Pressure for Improved Proteomic Analysis of FFPE Tissue and for Improved Sample Quality of Formalin-based Tissue Histology

Carol B Fowler, Dept. of Biophysics, Armed Forces Institute of Pathology, Rockville, MD

A Need for Improved Sample Inactivation and Extraction Methods to Support System Biology Analysis of Biological Threat Organisms

Bradford S. Powell, Bacteriology Division U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD

Convenient and Reliable Extraction of Borrelia burgdorferi from Ticks Using Pressure Cycling Technology (PCT) and the PCT Shredder

Richard C. Tilton, Ph.D., Medical Diagnostics Laboratories

The Real Jurassic Park: The Isolation of Proteins from Microorganisms Preserved in Amber Inclusions for 40 Million Years

Gary B. Smejkal1,2 1 Harvard Catalyst Laboratory for Innovative Translational Technologies, Boston, MA. 2 Politecnico di Milano, Department of Chemistry, Materials & Chemical Engineering, Milan, Italy

Pressure Cycling Technology (PCT) Augments Sensitivity of Detection and Robustness in Forensic DNA Analyses

Bruce Budowle, Ph.D., Department of Forensic and Investigative Genetics, Institute of Investigative Genetics, University of North Texas Health Science Center, Ft Worth, Texas

Rapid Sample Preparation Method for Analysis of N-Linked Glycans

Zoltan Szabo, Barnett Institute, Northeastern University, Boston, Massachusetts 02115

High-Pressure Assisted In-Gel Tryptic Digestion for Qualitative and Quantitative Characterization of Protein Mixtures

Melkamu Getie-Kebtie, FDA-CBER-NIH, Rockville Pike, Bethesda, MD 20892

High Pressure in Life Sciences -- Trends and Future Opportunities

Alexander Lazarev, Ph.D., Pressure BioSciences, Inc., S. Easton, Massachusetts 02375

Final Thoughts and Closing Remarks

Winston Patrick Kuo, DDS, DMSC, Director, Harvard Catalyst Laboratory for Innovative Translational Technologies (HC-LITT), Harvard Medical School Instructor

Dr. Nate Lawrence, Vice President of Marketing for PBI, said: "Pre-registrations have exceeded early estimates of one hundred people, so we are adjusting the room configuration to allow for more attendees. Registrants include research scientists; journal, magazine, and on-line newsletter reporters; potential strategic partners; customers; and the investment community, including fund managers, venture capitalists, investment bankers, research analysts, and investors. Together with our Harvard co-hosts, we are very excited to be part of this significant, seminal event."

Harvard CTSC is funded by a Clinical and Translational Science Award (Award #UL1 RR 025758) from the National Center for Research Resources (a part of the National Institutes of Health) and financial contributions from Harvard University and its affiliated academic healthcare centers. The mission of HC-LITT is to provide the Harvard research community with early access to new, enabling technologies.

Disclaimer

Harvard Catalyst -- The Harvard Clinical and Translational Science Center, the Harvard Catalyst Central Laboratory (HCCL), the Harvard Catalyst Laboratory for Innovative Translational Technologies (HC-LITT), the Proteomics Resource at Harvard School of Public Health (HPR), and the DoD do not endorse any company or product. The opinions expressed in this press release are those of PBI and do not represent the views of Harvard Catalyst, Harvard University and affiliated academic health care centers, National Center for Research Resources, the DoD, or the National Institutes of Health.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical and enzymatic reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the

meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the applications of cycled, ultra-high hydrostatic pressure (PCT) in biotechnology; that PCT is a powerful new proprietary platform; that PCT may be used to successfully break through bottlenecks and barriers that are preventing significant advancements in diagnostics and therapeutics; that PCT can enable new discoveries; the possible range of applications of PCT; the expected presenters and registrants at the Symposium; and that the Symposium will be an important event and an effective way to highlight the features and benefits of PCT. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of PCT and its PCT-dependent products; changes in customer's needs and technological innovations; other scientists may not achieve the same results with PCT reported by scientists in the past or by the scientists at the upcoming Symposium; the Company may not be successful in selling the PCT product line because scientists may not perceive the advantages of PCT over other methods, including the various areas to be discussed at the upcoming Symposium; due to unforeseen costs or delays, the Company may require additional working capital to fund its operations prior to the second half of 2011; and while the Company will require additional working capital in the second half of 2011, such additional working capital may not be available to the Company on acceptable terms or at all. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in PBI's Report on Form 10-Q for the quarter ended March 31, 2010, and other reports filed by PBI from time to time with the SEC. PBI undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website: http://www.pressurebiosciences.com

CONTACT: Pressure BioSciences, Inc.
Richard T. Schumacher, President & CEO
R. Wayne Fritzsche, Chairman
(508) 230-1828